Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2019 Mar 1;17(3):194-200. doi: 10.6004/jnccn.2018.7264.

Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer.

Author information

1
aDivision of Internal Medicine, New York Medical College, Westchester Medical Center, Valhalla, New York.
2
bDepartment of Physiology and Biophysics, and.
3
cInstitute for Computational Biomedicine, Weill Cornell Medicine, New York, New York.
4
dWake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina; and.
5
eDepartment of Medicine, Division of Hematology and Medical Oncology.
6
fDepartment of Pathology and Laboratory Medicine.
7
gEnglander Institute for Precision Medicine.
8
hDepartment of Urology, and.
9
iSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York.

Abstract

Urothelial carcinoma (UC) is a common and frequently lethal cancer. Despite the presence of genomic alterations creating dependency on particular signaling pathways, the use of targeted therapies in advanced and metastatic UC has been limited. We performed an integrated analysis of whole-exome and RNA sequencing of primary and metastatic tumors in a patient with platinum-resistant UC. We found a strikingly high ERBB2 mRNA expression and enrichment of downstream oncogenic ERBB2 signaling in this patient's tumors compared with tumors from an unselected group of patients with UC (N=17). This patient had an exceptional sustained response to trastuzumab. Our findings show that oncogenic addiction to ERBB2 signaling potentially predicts response to ERBB2-directed therapy of UC.

PMID:
30865916
DOI:
10.6004/jnccn.2018.7264

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center